Return to archive
EN · Issue 2 · 2026

SAFETY AND FEASIBILITY OF INTRACORONARY AUTOLOGOUS BONE MARROW CELL THERAPY IN ISCHEMIC CARDIOMYOPATHY: A PILOT CONTROLLED COHORT STUDY

Abstract

Introduction. Ischemic cardiomyopathy with reduced left ventricular ejection fraction (LVEF) is associated with limited functional reserve despite guideline-directed medical therapy. Intracoronary autologous bone marrow-derived cell therapy is considered an adjunctive regenerative strategy in patients with ischemic myocardial injury and chronic heart failure. Aim. To evaluate technical feasibility, 6-month safety, and exploratory functional changes after intracoronary autologous bone marrow-derived cell therapy in patients with ischemic cardiomyopathy and LVEF ≤40%. Methods. This single-center pilot-controlled cohort study included 20 patients with ischemic cardiomyopathy and LVEF ≤40%. Ten received intracoronary autologous bone marrow-derived cell therapy plus medical therapy, and 10 received medical therapy alone. Results. Of 27 screened patients, 20 were included, 10 in each group. At 6 months, mean LVEF changed from 30.2 ± 7.6% to 40.4 ± 10.0% in the cell therapy cohort and from 32.2 ± 9.9% to 28.5 ± 6.7% in controls. NT-proBNP changed from 686.4 ± 358.6 to 381.7 ± 168.1 pg/ml and from 1134.2 ± 1939.5 to 1242.6 ± 1737.4 pg/ml, respectively. Six-minute walk distance increased by 96.7 m and 33.2 m, respectively. NYHA class decreased from 2.7 ± 0.5 to 1.8 ± 0.6 in the cell therapy cohort and remained unchanged in controls. No serious clinical events were reported. Conclusion. Intracoronary autologous bone marrow-derived cell therapy was feasible and was not associated with reported serious adverse events over 6 months. Favorable cardiac and functional changes were observed, but findings remain exploratory and do not support definitive efficacy claims. Further randomized studies with complete product characterization, patient-level data and rigorous safety assessment are required.

Keywords

ischemic cardiomyopathyheart failurebone marrow cellsintracoronary infusionstem cell transplantationpilot project
How to cite
A. TOLEGENULY, A.M. MANSHARIPOVA, A.S. SEILGAZINOVA, M.S. LATIPBAYEVA, M.B. ASKAROV, B.S. ASSEMBEKOV. SAFETY AND FEASIBILITY OF INTRACORONARY AUTOLOGOUS BONE MARROW CELL THERAPY IN ISCHEMIC CARDIOMYOPATHY: A PILOT CONTROLLED COHORT STUDY. Vestnik KazNMU. 2026; 77(2). doi: 10.53065/kaznmu.2026.77.2.010